-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 J4ELNNhvgmB2E5tEYQhY6tlXTnXSnYmVNPmw1ET7jKKOy33uCns59HuCBcC0QQ3b
 dbfjPp2DdkADX/QYps/mwQ==

<SEC-DOCUMENT>0000012208-08-000035.txt : 20081014
<SEC-HEADER>0000012208-08-000035.hdr.sgml : 20081013
<ACCEPTANCE-DATETIME>20081014162626
ACCESSION NUMBER:		0000012208-08-000035
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20081007
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
FILED AS OF DATE:		20081014
DATE AS OF CHANGE:		20081014

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		081122610

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8kcover10072008.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES</TITLE>
<META NAME="author" CONTENT="Tom Brida">
<META NAME="date" CONTENT="10/14/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>UNITED STATES</B></P>
<P style="margin:0px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>CURRENT REPORT</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px" align=center><B>Date of Report: October 7, 2008</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Date of earliest event reported)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>BIO-RAD LABORATORIES, INC.</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Exact name of registrant as specified in its charter)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>Commission File Number: 1-7928</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=360></TD><TD width=7.133></TD><TD width=352.8></TD></TR>
<TR><TD width=360><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD width=352.8><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=360><P style="margin:0px" align=center><B>Delaware</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="margin:0px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(State or other jurisdiction of</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>incorporation or organization)</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(I.R.S. Employer</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Identification No.)</B></P>
</TD></TR>
</TABLE>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px" align=center><B>1000 Alfred Nobel Dr.</B></P>
<P style="margin:0px" align=center><B>Hercules, California 94547</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Address of principal executive offices, including zip code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px" align=center><B>(510) 724-7000</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Registrant&#146;s telephone number, including area code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=562.733></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=562.733><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=565.6></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=565.6><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=616.267></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=616.267><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=615></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=615><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><B>&nbsp;ITEM 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">On October 7, 2008, Bio-Rad Laboratories, Inc. (the &#147;Company&#148;) announced its intention to transfer the listing of its common stock, including its Class A Common Stock and Class B Common Stock, from the NYSE Alternext (formerly, the American Stock Exchange or AMEX) to the NYSE Big Board. &nbsp;A copy of the press release is furnished as Exhibit 99.1 to this report. &nbsp;The Company has also notified the NYSE Alternext of its intention to transfer the listing of its common stock to the NYSE Big Board. &nbsp;The Company anticipates that its common stock will begin trading on the NYSE Big Board on or about October 24, 2008. &nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=492.667></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px"><B>ITEM 9.01</B></P>
</TD><TD valign=top width=492.667><P style="margin:0px"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=60></TD><TD width=24></TD><TD width=497.533></TD></TR>
<TR><TD width=60><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD width=497.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=60><P style="margin:0px"><B>Exhibit</B></P>
<P style="margin:0px"><B>Number&nbsp;</B></P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=497.533><P style="margin:0px"><BR></P>
<P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=60><P style="margin-top:2.2px; margin-bottom:0px" align=right>99.1&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin-top:2.2px; margin-bottom:0px">&nbsp;</P>
</TD><TD valign=bottom width=497.533><P style="margin-top:2.2px; margin-bottom:0px">Press release of Bio-Rad Laboratories, Inc. dated October 7, 2008</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px">&nbsp;&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=50.867></TD><TD width=136.333></TD><TD width=29.467></TD><TD width=29.467></TD><TD width=4></TD><TD width=253.867></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=287.333 colspan=3><P style="margin:0px">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="margin:0px">Date:</P>
</TD><TD style="border-bottom:1px solid #000000" width=136.333><P style="margin:0px">October 14, 2008</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="margin:0px">By:</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=257.867 colspan=2><P style="margin:0px">Norman Schwartz</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">President and Chief Executive Officer</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="margin:0px">&nbsp;</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=253.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<A NAME="id_11"></A><A NAME="id_12"></A><P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>EXHIBIT INDEX</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=34.2></TD><TD width=28.267></TD><TD width=513.533></TD></TR>
<TR><TD width=34.2><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD width=513.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=34.2><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Exhibit</B></P>
<P style="line-height:12px; margin:0px; font-size:9.333px"><B>Number</B></P>
</TD><TD valign=bottom width=28.267><P style="margin:0px; font-size:9.333px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=513.533><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=34.2><P style="margin:0px">99.1</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=513.533><P style="margin:0px">Press release of Bio-Rad Laboratories, Inc. dated October 7, 2008</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exh99110142008.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="08/05/2008">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:604.8px"><P style="margin:0px" align=right><BR></P>
<P style="line-height:18.667px; margin:0px; font-size:16px" align=right><U>Exhibit 99.1</U></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:20px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:17.333px" align=center><FONT FACE="HelveticaNeueLT Std"><B>BIO-RAD ANNOUNCES INTENT TO LIST ON THE </B></FONT></P>
<P style="line-height:20px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:17.333px" align=center><B>NEW YORK STOCK EXCHANGE</B></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin-top:2.467px; margin-bottom:2.467px; font-family:HelveticaNeueLT Std; font-size:14.667px"><B>HERCULES, CA &#150; October 7, 2008</B> <B>&#150;</B> Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced its intent to transfer trading of its stock to the New York Stock Exchange (&#147;NYSE&#148;) from the American Stock Exchange (&#147;AMEX&#148;). Bio-Rad will continue to trade its stock under two ticker symbols: BIO (for its Class A Common Stock) and BIOb (for its Class B Common Stock). The Company anticipates that trading on the NYSE Big Board will begin on or about October 24, 2008.</P>
<P style="line-height:21.333px; margin:2.467px"><BR></P>
<P style="line-height:21.333px; margin-top:2.467px; margin-bottom:2.467px; font-family:HelveticaNeueLT Std; font-size:14.667px">&#147;We are pleased to join the New York Stock Exchange and believe our shareholders will benefit from the NYSE&#146;s brand, reputation, and trading efficiencies,&#148; said Norman Schwartz, Bio-Rad President and Chief Executive Officer. &nbsp;</P>
<P style="line-height:21.333px; margin:2.467px"><BR></P>
<P style="line-height:21.333px; margin-top:2.467px; margin-bottom:2.467px; font-family:HelveticaNeueLT Std; font-size:14.667px">&#147;We welcome Bio-Rad Laboratories&#146; decision to list on the New York Stock Exchange,&#148; said Duncan L. Niederauer, CEO, NYSE Euronext. &#147;For over 50 years, Bio-Rad has built a reputation of being a leading innovator of tools and services in the life science research and clinical diagnostics markets. With the company&#146;s move to the NYSE, Bio-Rad joins the premier marketplace for the global leaders in the healthcare industry. We welcome the Bio-Rad team and look forward to providing the highest levels of market quality and service to the company and its shareholders.&#148; </P>
<P style="line-height:21.333px; margin:2.467px"><BR></P>
<P style="line-height:21.333px; margin-top:2.467px; margin-bottom:2.467px; font-family:Helvetica 45 Light; font-size:14.667px"><FONT FACE="Helvetica 45 Light"><B>About Bio-Rad</B></FONT></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px"><FONT FACE="HelveticaNeueLT Std">Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of </FONT></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">scientific discovery for more than 50 years, manufacturing and distributing a broad </P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research </P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px">institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-family:HelveticaNeueLT Std; font-size:14.667px; page-break-before:always">6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com. </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:normal; margin:0px; font-family:HelveticaNeueLT Std"><I>This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;continue,&#148; or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the &#147;Risk Factors&#148; in the Company&#146;s public reports filed with the Securities and Exchange Commission, including the Company&#146;s Annual Report on Form 10-K for th
e fiscal year ended December 31, 2007, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. &nbsp;Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements</I>. <FONT COLOR=#0000FF>&nbsp;</FONT></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-family:HelveticaNeueLT Std; font-size:14.667px"><B>For more information, contact: </B><FONT COLOR=#0000FF>&nbsp;</FONT></P>
<P style="line-height:21.333px; margin:0px; padding-left:24px; padding-right:43.2px; text-indent:-24px; font-family:HelveticaNeueLT Std; font-size:14.667px">Tina Cuccia, Corporate Communications Manager</P>
<P style="line-height:21.333px; margin:0px; padding-left:24px; padding-right:43.2px; text-indent:-24px; font-family:HelveticaNeueLT Std; font-size:14.667px">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:21.333px; margin:0px; padding-left:24px; padding-right:43.2px; text-indent:-24px; font-family:HelveticaNeueLT Std; font-size:14.667px">510-724-7000 </P>
<P style="line-height:21.333px; margin:0px; padding-left:24px; padding-right:43.2px; text-indent:-24px; font-family:HelveticaNeueLT Std; font-size:14.667px">tina_cuccia@bio-rad.com<FONT FACE="HelveticaNeue LightExt"> </FONT></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
